Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1966]

Durvalumab with BCG and maintenance therapy improves disease-free survival in...

Dr Maria De Santis - Charité University Hospital, Berlin, Germany

Durvalumab with BCG and maintenance therapy improves disease-free survival in high-risk NMIBC ( Dr Maria De Santis - Charité University Hospital, Berlin, Germany )

Perioperative enfortumab vedotin plus pembro improves survival and pCR in...

Prof Christof Vulsteke - Maria Middelares General Hospital, Ghent, Belgium

Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC ( Prof Christof Vulsteke - Maria Middelares General Hospital, Ghent, Belgium )

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine...

Dr Charles E. Geyer - University of Pittsburgh School of Medicine, Pittsburgh...

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer ( Dr Charles E. Geyer - University of Pittsburgh School of Medicine, Pittsburgh, USA )

Tarlatamab shows manageable safety profile with fewer toxicities than chemo in...

Prof Martin Schuler - Essen University Hospital, Essen, Germany

Improving efficacy and toxicity reporting - and treatment insights from an...

Dr Ross Camidge - University of Colorado School of Medicine, Aurora, Colorado

Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient ( Dr Ross Camidge - University of Colorado School of Medicine, Aurora, Colorado )

WCLC 2025: Latest in EGFR positive NSCLC

Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil...

WCLC 2025: Latest in EGFR positive NSCLC ( Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil-Bazo )

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic...

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2...

Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results ( Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida...

ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in...

Dr Kunvar Harsh Upveja - Biocon Biologics, Bengaluru, India

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in Morocco ( Dr Kunvar Harsh Upveja - Biocon Biologics, Bengaluru, India )

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma...

Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases ( Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA )

More from ecancer